ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1576	National Cancer Institute	Html	en	Prostate Cancer Screening (PDQ®)–Patient Version	Expert-reviewed information summary about tests used to detect or screen for prostate cancer.	PDQ Screening 0.238955 prostate gland 0.262783 following PDQ summaries 0.255959 Cancer Information Service 0.234967 PDQ cancer information 0.447798 Prevention Editorial Board 0.248763 men 0.210517 National Cancer Institute 0.335949 clinical trials 0.389256 PDQ documents 0.200757 test result 0.223183 benign prostatic hyperplasia 0.273839 cancer information summary 0.326548 newly diagnosed prostate 0.284247 clinical trial 0.213023 new treatment 0.208327 breast cancer prevention 0.217981 early cancer detection 0.236129	Cancer screening trials 0.28054 test 0.242059 Cancer Care page 0.221557 PDQ database 0.205174 prostate cancer gene 0.339499 NCI’s PDQ 0.209119 prostate cancer screening 0.411947 PDQ summary 0.286479 cancer symptoms 0.211597 NCI PDQ cancer 0.287762 prostate cancer 0.971006 tests 0.264624 bigger prostate 0.262229 PSA test 0.20487 Prostate Cancer Prevention 0.350483 cancer information summaries 0.242796 comprehensive cancer information 0.243032 high PSA level 0.200418	CLICK HERE
1580	National Cancer Institute	Html	en	Skin Cancer Screening (PDQ®)–Patient Version	Having a skin exam to screen for skin cancer has not been shown to decrease your chance of dying from skin cancer. Learn about this and other tests that have been studied to detect or screen for skin cancer in this expert reviewed summary.	PDQ Screening 0.323371 skin cancer 0.833312 cancer treatment 0.285886 cancer screening methods 0.360926 United States 0.282138 ongoing clinical trials 0.355632 screening tests 0.287638 cancer cells 0.293854 following PDQ summaries 0.338661 Cancer Information Service 0.328048 PDQ cancer information 0.497713 squamous cells 0.320712 squamous cell skin 0.32842 white men 0.281879 Prevention Editorial Board 0.34433 treatment clinical trials 0.288708 National Cancer Institute 0.431189 clinical trials 0.547197 PDQ documents 0.289835 inner layer 0.288892 test result 0.316842 cancer information summary 0.417477 melanoma skin cancer 0.385616 new treatment 0.294602	breast cancer prevention 0.311531 skin cancer screening 0.419518 Cancer screening trials 0.367401 NCI website 0.290521 Regular skin checks 0.306952 Cancer Care page 0.315809 PDQ database 0.293213 latest published information 0.29227 risk factor 0.309102 NCI’s PDQ 0.299274 PDQ summary 0.314752 UV radiation 0.308073 cancer symptoms 0.303698 doctor 0.289249 NCI PDQ cancer 0.373425 tests 0.320045 cancer information summaries 0.334989 nonmelanoma skin cancer 0.420432 comprehensive cancer information 0.335151 basal cell carcinoma 0.354359 cancer 0.95489 basal cells 0.2875 squamous cell carcinoma 0.357881	CLICK HERE
1766	National Cancer Institute	Html	en	Accidents at Nuclear Power Plants and Cancer Risk	A fact sheet about cancer risks associated with accidents at nuclear power plants.	Atomic Radiation 0.316376 Radiation risks 0.325562 radiation exposures 0.328269 nuclear accident sites 0.293301 Radiation Research 0.323015 low levels 0.272065 nuclear power plant 0.97677 I-131 exposure 0.297263 radiation sickness 0.405841 high doses 0.352667 radiation emergencies 0.31438 Chernobyl nuclear power 0.302487 Additional radioactive isotopes 0.311741 dangerous radioactive isotopes 0.306851 cancer patients 0.299868 greatest cancer risks 0.294897 cancer risks 0.312758 radioactive materials 0.379547 radiation therapy 0.335122 unstable isotopes 0.274 Radiation Effects Research 0.350011 external radiation 0.312725 power plant disaster 0.278559 radioactive isotopes 0.53284 ionizing radiation 0.412892	health effects 0.355744 future nuclear accidents 0.300229 nuclear reactors 0.284713 power plant accident 0.397996 nuclear weapons explosions 0.282249 thyroid gland 0.292634 thyroid cancer 0.388789 radiation exposure 0.375545 power plant accidents 0.566854 Radiation Emergency Medical 0.344768 I-131 0.306486 radioactive exposure 0.273465 National Cancer Institute 0.340697 specific radioactive materials 0.295979 breast cancer risk 0.282358 Radiation Epidemiology Branch 0.341242 Chernobyl-related thyroid cancer 0.291023 radiation 0.697647 cancer risk 0.309268 et al 0.275755 medical x-ray machines 0.33168 cancer 0.423405 Chernobyl accident 0.42803 certain radioactive isotopes 0.3079	CLICK HERE
1863	National Cancer Institute	Html	es	Tratamiento de la leucemia de células pilosas (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento de la leucemia de células pilosas.	cell leukemia treated 0.413444 cell leukemia patients 0.427269 long-term follow-up 0.427434 Rituximab with pentostatin 0.40359 Peaud PY 0.40245 hairy cell leukaemia 0.411122 initially with pentostatin 0.406363 Foucar MK 0.403895 leukemia patients treated 0.417121 leukemia following treatment 0.406508 células pilosas 0.473847 treated with rituximab 0.403745 Instituto Nacional 0.402568 cell leukemia following 0.408562 Else M 0.404329 with pentostatin 0.442439 or refractory hairy 0.403457 VH4-34+ hairy cell 0.404297 Natl Cancer Inst 0.402731 Federico M 0.402782 Leuk Lymphoma 0.424893 long term 0.40908 patients treated with 0.423309 Burian C 0.403658 Matutes E 0.403796	leukemia treated with 0.41301 patients with hairy 0.610395 following treatment with 0.408927 Italian Cooperative Group 0.40697 hairy-cell leukemia with 0.408245 relapsed or refractory 0.403586 National Cancer Institute 0.404377 after treatment with 0.408757 untreated patients with 0.407444 with poor prognosis 0.40323 with 2-CdA 0.403201 cell leukemia with 0.426877 treatment with 0.420376 hairy cell leukemia 0.998262 Clin Oncol 0.444146 treated with pentostatin 0.422653 leukemia with pentostatin 0.404444 leukemia after treatment 0.406381 Long term results 0.402405 treated with 0.429875 treated initially with 0.406289 previously untreated patients 0.40321 PDQ Sofocos 0.402915 cell leukemia after 0.412869	CLICK HERE
1948	National Cancer Institute	Html	es	Tratamiento de los tumores extragonadales de células germinativas (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento de los tumores extragonadales de células germinativas.	siguientes grupos 0.500793 PDQ Tratamiento 0.447593 células madre 0.930362 presente sección 0.425406 pronóstico intermedio 0.514735 células germinativas seminomas 0.532192 células germinativas benignos 0.688648 tratamiento ensayos 0.59373 Physician Data Query 0.482499 coriónica humana beta 0.478909	alta dosis 0.47522 rayos x 0.439813 siguientes enlaces 0.419924 teratomas benignos 0.520514 National Cancer Institute 0.419632 tumores benignos 0.511502 marcadores tumorales afp 0.494552 siguientes riesgos 0.414221 siguientes sumarios 0.481053 Instituto Nacional 0.537154	CLICK HERE
1990	National Cancer Institute	Html	es	Comunicación en la atención del cáncer (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos sobre la comunicación con el paciente de cáncer y su familia, incluso los aspectos distintivos de la comunicación con pacientes de cáncer, los factores que afectan la comunicación y el entrenamiento de las aptitudes para la comunicación.	with breast 0.27121 patient communication research 0.255921 bad news 0.239568 Street RL Jr 0.270308 giving bad news 0.237103 Dukes KA 0.247903 difficult communication tasks 0.239533 informed consent 0.381629 Curr Opin Oncol 0.303353 patient decision-making 0.248603 Communication skills training 0.283908 American Society 0.336788 CA Cancer 0.26685 women with 0.382665 early breast 0.242745 Fallowfield L 0.241349 clinical trial 0.65623 cancer care 0.822992 Visser MR 0.248358 cancer patients 0.961853 Communication competency 0.236584 Oncology Educational Book 0.262112 Silliman RA 0.275555 patients with 0.301983 Baile WF 0.377394	patients with breast 0.241546 Cancer communication 0.28025 Patient-physician communication 0.262767 Soc Sci Med 0.536666 Patient Educ Couns 0.328692 Johnson Palensky JE 0.238609 Jenkins V 0.238673 Pediatr Blood Cancer 0.265712 Ong LM 0.251154 Clinical Oncology Educational 0.287455 National Cancer Institute 0.266416 with early-stage breast 0.27671 with patient satisfaction 0.238783 clinical oncology 0.509423 oncology clinical trials 0.240093 Sullivan LM 0.248063 Clin Oncol 0.716929 Thirty-Fourth Annual Meeting 0.246656 diagnosed breast patients 0.240688 patient satisfaction 0.273273 mujeres pacientes 0.274298 emotional health 0.24615 paciente capta 0.243139 Butow PN 0.59292	CLICK HERE
2048	National Cancer Institute	Html	es	Pruebas de Papanicolaou y del virus del papiloma humano (VPH)	Hoja informativa que describe los exámenes selectivos de detección del cáncer de cérvix, los cuales incluyen la prueba de Papanicolaou y la prueba de los virus del papiloma humano.	Lancet Oncology 0.30494 alta probabilidad 0.305241 Clinical Pathology 0.316699 siguientes categorías 0.313238 undergoing concurrent testing 0.307924 American Society 0.338185 Schiffman M 0.323335 pruebas conjuntas 0.308272 Sociedad Estadounidense 0.311719 Task Force Recommendation 0.307945 Preventive Services Task 0.350595 Cervical Pathology 0.322689 low-grade squamous 0.308742 Roche Molecular Systems 0.307924 Estados Unidos 0.346024 cervical cancer 0.362845 Clinical Pathology screening 0.309437 cobas hpv test 0.3092 PubMed Abstract 0.387591 categoría cin-2 0.304985 categoría cin-3 0.305133 human papillomavirus 0.356046 Cancer Journal 0.30689 atypical squamous cells 0.360558 Sistema Bethesda 0.324914	Patología Cervical 0.309863 lesiones asc-h 0.305566 categorías cin-2 0.305175 United States Preventive 0.309063 cuidado médico 0.306651 lesiones asc-us 0.30675 Katki HA 0.31204 alto riesgo 0.931083 clinical practice 0.304727 Drug Administration 0.304664 cervical cytology 0.30862 Servicios Preventivos 0.304816 Wacholder S 0.311753 resultado asc-us 0.312665 papillomavirus testing 0.305257 HPV cotesting 0.306351 resultados benignos 0.305213 Services Task Force 0.349973 cervical intraepithelial neoplasia 0.314986 mejores resultados 0.304652 Cancer Institute 0.314518 graves anomalías 0.316853 infecciones pasajeras 0.309673 squamous cell carcinoma 0.313148	CLICK HERE
2065	National Cancer Institute	Html	es	Antecedentes de reproducción y riesgo de cáncer	Hoja informativa que describe lo que se sabe acerca de la relación entre el embarazo, el aborto espontáneo, el aborto provocado, el tratamiento de la fecundidad y el riesgo de cáncer.	receptor status 0.304466 long-term risk 0.309373 Pregnancy characteristics 0.303667 Pregnancy hormones 0.303713 case-control study 0.303107 reproductive factors 0.331813 British Journal 0.324023 Breast Cancer Research 0.395793 registry-based study 0.302906 risk factors 0.312191 collaborative reanalysis 0.305888 EPIC study 0.302933 population-based study 0.303204 Collaborative Group 0.305178 PubMed Abstract 0.987212 menor riesgo 0.316145 California Teachers Study 0.303614 maternal breast 0.310955 pregnancy is not 0.304559 altas concentraciones 0.302587 International Journal 0.309155 Reproductive Medicine 0.30288 Bernstein L 0.30839 temprana edad 0.305212 Titus-Ernstoff L 0.304113	after hormonal treatments 0.303615 Gynecologic Practice 0.305924 induced abortion 0.304146 mayores riesgos 0.303963 from epidemiological findings 0.304602 Hormonal Factors 0.309423 Endocrine-Related Cancer 0.31659 Hoover RN 0.3041 Mammary Gland Biology 0.302896 during pregnancy 0.303751 epidemiological studies 0.31198 subsequent risk 0.308543 prospective cohort study 0.304098 ACOG Committee Opinion 0.303117 Leeuwen FE 0.303776 breast cancer 0.953779 risk according 0.308782 pregnancy termination 0.303569 Romundstad PR 0.309387 vitro fertilization 0.304038 Colditz GA 0.304081 prospective study 0.303107 New England Journal 0.303804 systematic reviews 0.304009	CLICK HERE
15609	National Cancer Institute	Html	es	Tratamiento de los tumores vasculares infantiles (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento de los tumores vasculares infantiles.	problemas pasajeros 0.409161 lesiones benignas 0.409862 piel vecina 0.430821 efectos secundarios meses 0.423036 importantes preguntas 0.409508 siguientes especialistas 0.418218 siguientes síndromes 0.413185 rayos x 0.412063 niño ayuda 0.413721 escamas llamadas placas 0.409897 tumores benignos 0.516528 tumor vascular benigno 0.534618 Instituto Nacional 0.412348 alta potencia 0.411312 células llamadas 0.410367 tumores vasculares benignos 0.9178 venas sanas vecinas 0.421159 nuevos tipos 0.412108 sangre circula 0.414383 medicamentos propranolol hydrochloride 0.437459 angiofibroma nasofaríngeo 0.468048 hemangioendotelioma epitelioides 0.436434 once tipos 0.436191 glándula tiroides 0.427118 posibles efectos tardíos 0.424225	adultos jóvenes 0.418525 siguientes tumores 0.604051 granulomas piógenos 0.445724 hemangioma capilar lobulillar 0.505924 siguientes tipos 0.41901 ondas sonoras 0.412577 efectos tardíos 0.50862 PDQ Efectos tardíos 0.43716 vías respiratorias 0.428225 tarde.ampliar ecografía 0.413763 granuloma piógeno 0.509033 IRMN).Ampliar Imágenes 0.410245 sección opciones 0.41178 hemangioendoteliomas epitelioides 0.418326 PDQ Tratamiento 0.421361 afección llamada esclerosis 0.414532 siguientes signos 0.417619 siguientes casos 0.414811 Physician Data Query 0.425443 propranolol iv 0.42341 insuficiencia cardíaca 0.475544 hemangioma epitelioide 0.568564 siguientes pruebas 0.434586 angiofibromas nasofaríngeos juveniles 0.440153	CLICK HERE
17171	National Cancer Institute	Html	es	PC-SPES (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos sobre el uso de PC-SPES como tratamiento del cáncer de próstata. Nota: La información contenida en este sumario ya no se actualiza y se ofrece solo con fines de consulta.	médico herborista 0.418438 Centro Nacional 0.430037 New Hampshire Avenue 0.420405 Drug Administration 0.412734 NCI Best Case 0.437012 datos bibliográficos pubmed 0.422243 siguientes preguntas 0.413766 demostró efectos 0.424258 siguientes riesgos 0.417668 seguro médico 0.412292 múltiples problemas 0.418438 Instituto Nacional 0.517971 acupuntura ayuda 0.412243 Salud Complementaria 0.450225 Visuals Online 0.415643	complementarias revisa 0.422417 Physician Data Query 0.491682 Estados Unidos 0.863449 actúa pc-spes 0.442835 libre uso 0.415953 suficiente cantidad 0.41905 página manejo 0.414584 ¿El tratamiento 0.421322 Nueva York 0.418373 ¿Los beneficios 0.413162 siguientes medicamentos 0.438285 Series Program 0.413051 medicina complementaria 0.925538 diferentes lotes 0.423892	CLICK HERE